Core Insights - Company reported a revenue of 21.675 billion with a year-on-year growth of 3.39% [1] - Net profit attributable to shareholders reached 1.815 billion, reflecting a year-on-year increase of 7.01% [1] - Basic earnings per share stood at 1.03 yuan [1] Financial Performance - The company plans to distribute a cash dividend of 3.5 yuan per 10 shares (tax included) [1] - Revenue from sales and agency services amounted to 1.084 billion, with a significant year-on-year growth of 59% [1] - The company is benefiting from the approval and launch of new products, contributing to the growth in innovative product revenue [1]

第十一届董事会独立董事专门会议2025年第一次会议决议 华东医药股份有限公司（以下简称"公司"）第十一届董事会独立 董事专门会议 2025 年第一次会议于 2025 年 08 月 18 日（星期一）在 公司会议室以通讯的方式召开。会议通知已于 2025 年 08 月 15 日通 过邮件的方式送达各位独立董事。本次会议应出席独立董事 4 人，实 际出席独立董事 4 人。 会议由全体独立董事共同推举黄简女士担任召集人和主持人。会 议召开符合有关法律、法规、规章和《公司章程》《独立董事工作制 度》的规定。经各位独立董事认真审议，会议形成了如下决议： 1、审议通过《关于与专业投资机构共同投资设立专项医药产业 投资基金暨关联交易的议案》 表决结果：4 票同意，0 票反对，0 票弃权。 华东医药股份有限公司 独立董事： 黄简 王如伟 魏淑珍 薛丽香 2025 年 08 月 20 日 本次公司参与投资设立生物医药产业投资基金暨关联交易，有利 于公司借助专业机构的投资经验和能力，提高对投资标的运作的专业 性，不会对公司的独立性构成影响，符合公司及全体股东的利益，有 利于公司的长远发展。本次关联交易对公司日常经营及财务状况不会 ...

Core Viewpoint - Huadong Medicine reported a steady growth in its financial performance for the first half of 2025, with revenue reaching 21.675 billion yuan, a year-on-year increase of 3.39%, and a net profit of 1.815 billion yuan, up 7.01% [1] Financial Performance - The company achieved a total revenue of 21.675 billion yuan in the first half of 2025, reflecting a 3.39% increase year-on-year [1] - The net profit attributable to shareholders was 1.815 billion yuan, marking a 7.01% growth, while the net profit excluding non-recurring items was 1.762 billion yuan, up 8.40% [1] - A mid-year dividend of 614 million yuan is proposed, representing 33.83% of the net profit for the first half of 2025 [1] Business Growth and Product Commercialization - Huadong Medicine's core subsidiary, Zhongmei Huadong, reported a revenue of 7.317 billion yuan, a 9.24% increase, and a net profit of 1.580 billion yuan, up 14.09% [2] - The innovative product sales and agency service revenue reached 1.084 billion yuan, with a significant growth of 59% [2] - The CAR-T product, Zekai Ze, has expanded its market coverage, with over 20 provinces certified and more than 100 insurance projects included for reimbursement [2] R&D and Innovation - The company invested 1.484 billion yuan in R&D, a 33.75% increase, with direct R&D spending at 1.174 billion yuan, up 54.21% [6] - Huadong Medicine is advancing over 80 innovative drug pipelines, focusing on oncology, endocrinology, and autoimmune diseases [6][7] - The ADC product pipeline is progressing well, with several candidates in clinical trials and receiving orphan drug designation from the FDA [8] Industrial Microbiology and Aesthetic Medicine - The industrial microbiology segment achieved sales of 368 million yuan, a 29% increase, with significant growth in various sub-segments [10] - The aesthetic medicine division has launched multiple products, with strong market reception and ongoing registration efforts for new products [11][12] - The company aims to enhance its global presence and continue driving innovation in both pharmaceutical and aesthetic sectors [12]

Core Viewpoint - The company has approved the establishment of a joint investment fund aimed at the pharmaceutical industry, with a total commitment of RMB 2 billion, to enhance its competitive edge in innovative sectors [1] Investment Fund Details - The investment fund, named "Hangzhou Fuguang Hongze Equity Investment Partnership (Limited Partnership)," will be co-established with Shanghai Fuguang Private Equity Fund Management Co., Ltd., Hangzhou Industrial Investment Co., Ltd., and Hangzhou Gongshu Industrial Fund Co., Ltd. [1] - The total subscribed capital of the fund is RMB 2 billion, with the company contributing RMB 980 million, representing a 49% stake [1] Investment Focus - The fund will primarily invest in sectors such as innovative pharmaceuticals, medical aesthetics, health and wellness, animal health, and other areas related to biology, medicine, and health that align with Hangzhou's five major industrial ecosystems [1] - The objective of the fund is to reduce the upfront costs associated with identifying and introducing high-quality innovative projects, diversify investment risks, and consolidate resources to strengthen the company's core competencies in key areas like innovative pharmaceuticals, medical aesthetics, and industrial microbiology [1]

证券代码：000963 证券简称：华东医药 公告编号：2025-083 华东医药股份有限公司 关于与专业投资机构共同投资设立专项医药产业投资 基金暨关联交易的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 华东医药股份有限公司（以下简称"公司"、"本公司"）于 2025 年 08 月 18 日召开第十一届董事会第二次会议，审议通过了《关于与 专业投资机构共同投资设立专项医药产业投资基金暨关联交易的议 案》，现将具体情况公告如下： 一、本次对外投资暨关联交易概述 （一）对外投资概述 为进一步丰富公司产业投资生态圈，拓展产业链布局，更好地借 助专业机构的专业力量及资源优势，整合各方资源，提高公司的核心 竞争力，2025 年 08 月 18 日，公司作为有限合伙人，与普通合伙人、 执行事务合伙人暨基金管理人上海福广私募基金管理有限公司（以下 简称"上海福广"）、有限合伙人杭州产业投资有限公司（以下简称"杭 州产投"）、有限合伙人杭州拱墅产业基金有限公司（以下简称"拱墅 产业"）共同签署了《杭州福广鸿泽股权投资合伙企业（有限合伙） 合伙协议》，共同投资设立"杭州 ...

智通财经APP讯，华东医药(000963.SZ)发布2025年半年度报告，该公司营业收入为216.75亿元，同比增 长3.39%。归属于上市公司股东的净利润为18.15亿元，同比增长7.01%。归属于上市公司股东的扣除非 经常性损益的净利润为17.62亿元，同比增长8.40%。基本每股收益为1.0293元。 报告期内核心子公司中美华东整体经营继续保持良好增长趋势，实现营业收入73.17亿元(含CSO业务)， 同比增长9.24%，实现归母净利润15.80亿元，同比增长14.09%，净资产收益率12.16%。 此外，拟向全体股东每10股派发现金红利3.50元(含税)。 ...

Core Viewpoint - Huadong Medicine Co., Ltd. reported a steady growth in revenue and net profit for the first half of 2025, reflecting the company's robust operational performance and strategic initiatives in various business segments [12][20]. Financial Performance - The company achieved operating revenue of approximately 21.67 billion yuan, a year-on-year increase of 3.39% compared to 20.97 billion yuan in the same period last year [9]. - Net profit attributable to shareholders reached approximately 1.76 billion yuan, up 8.40% from 1.63 billion yuan in the previous year [9]. - The basic earnings per share increased by 6.39% to 1.03 yuan from 0.97 yuan [9]. Business Segments Overview - The company operates in four main business segments: pharmaceutical manufacturing, pharmaceutical commerce, medical aesthetics, and industrial microbiology [12][10]. - The pharmaceutical manufacturing segment focuses on chronic diseases, immunology, oncology, and endocrine disorders, with a strong product pipeline and international certifications [12][10]. - The pharmaceutical commerce segment has established a comprehensive logistics network, positioning the company as a leader in Zhejiang province and among the top ten in national pharmaceutical wholesale [12][10]. Innovation and R&D - The company invested approximately 1.48 billion yuan in R&D, marking a 33.75% increase, with direct R&D expenses accounting for 15.97% of pharmaceutical manufacturing revenue [20]. - The innovation strategy has led to the approval and commercialization of several new drugs, contributing significantly to revenue growth [14][16]. Market Strategy - The company is enhancing its market presence through a multi-channel approach, focusing on both hospital and retail markets, and leveraging digital platforms for better customer engagement [15][22]. - Strategic partnerships and collaborations with international pharmaceutical companies are being pursued to expand product offerings and market reach [12][10]. Operational Efficiency - The company is implementing advanced production management systems, including automation and digitalization, to improve operational efficiency and reduce costs [19][20]. - The establishment of new production facilities is aimed at supporting the commercialization of innovative drugs and enhancing production capabilities [19][20].

Core Viewpoint - The report highlights the financial performance and operational developments of East China Pharmaceutical Co., Ltd. for the first half of 2025, showcasing growth in revenue and net profit, alongside strategic advancements in various business segments [1][9][10]. Financial Performance - The company achieved a total revenue of approximately 21.67 billion yuan, representing a year-on-year increase of 3.39% [1]. - The net profit attributable to shareholders reached approximately 1.81 billion yuan, marking a 7.01% increase compared to the previous year [1]. - The basic earnings per share rose to 1.0293 yuan, reflecting a growth of 6.39% [2]. - The net cash flow from operating activities was approximately 2.46 billion yuan, up by 7.98% [2]. Business Segments Overview Pharmaceutical Manufacturing - The company focuses on specialized, chronic, and unique medication fields, with a comprehensive manufacturing system aimed at international markets [5]. - Key therapeutic areas include chronic kidney disease, immunology, oncology, endocrinology, digestive systems, and cardiovascular diseases [5]. - The company has established partnerships with international research firms and multinational pharmaceutical companies for product development [5]. Pharmaceutical Commerce - The pharmaceutical commercial segment emphasizes drug distribution, medical devices, and herbal medicine, supported by an intelligent logistics network [6]. - The company operates a comprehensive distribution model that integrates both hospital and retail channels, maintaining a leading position in Zhejiang province [6]. Aesthetic Medicine - The aesthetic medicine division has developed a diverse product matrix, with over 20 products launched globally and several in the pipeline [7]. - The company aims to become a leading provider of comprehensive aesthetic solutions, leveraging its international platform [7]. Industrial Microbiology - The focus is on synthetic biology innovation and the upgrade of the biopharmaceutical industry, with a strong emphasis on xRNA raw materials and health-related biological materials [8]. - The company has established a comprehensive R&D and production system for microbial drugs, maintaining industry-leading standards [8]. Strategic Developments - The company has made significant investments in R&D, with expenditures reaching approximately 1.48 billion yuan, a 33.75% increase year-on-year [18]. - The company is advancing its innovation strategy, with a focus on expanding its product pipeline and enhancing operational efficiency [18]. - The aesthetic medicine segment is adapting to market changes, with a focus on strengthening its brand and expanding its product offerings [21][22]. Market Position and Future Outlook - The company is well-positioned to capitalize on the growing demand for innovative pharmaceutical products and aesthetic solutions, with a robust pipeline and strategic partnerships [9][10]. - The ongoing development of new products and market expansion initiatives is expected to drive future growth and enhance competitive advantages [11][13].

公 司 2025 年 1-6 月 实 现 归 属 于 上 市 公 司 股 东 的 净 利 润 为 元 ， 截 至 2025 年 06 月 30 日 ， 公 司 合 并 报 表 累 计 未 分 配 利 润 为 （以上财务数据均未经审计。 证券代码：000963 证券简称：华东医药 公告编号：2025-081 华东医药股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、2025年半年度利润分配方案的审议程序 华东医药股份有限公司（以下简称"公司"）于2025年05月15日召 开的2024年度股东大会审议通过了《关于提请股东大会授权董事会制 定2025年中期分红方案的议案》，股东大会同意授权董事会根据股东 大会决议在符合利润分配的条件下制定具体的分红方案，2025年中期 分红的前提条件为：（1）公司在当期实现合并报表归属于上市公司 股东的净利润保持稳定增长；（2）公司现金流可以满足正常经营和 持续发展的需求。中期分红金额上限为相应期间归属于上市公司股东 的净利润的50%，下限为人民币5亿元（含税）。 公司于2025年08月18日召开了第十一届董事会第二 ...

证券代码：000963 证券简称：华东医药 公告编号：2025-079 华东医药股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 华东医药股份有限公司（以下简称"公司"）第十一届董事会第二 次会议的通知于2025年08月07日以书面和电子邮件等方式送达各位 董事，并于2025年08月15日发出会议补充通知新增议案《关于与专业 投资机构共同投资设立专项医药产业投资基金暨关联交易的议案》， 会议于2025年08月18日（星期一）在公司会议室以现场并结合通讯方 式召开。会议应参加董事11名，实际参加董事11名。会议由公司董事 长主持。会议的召开和表决程序符合《公司法》《公司章程》的有关 规定，会议合法有效。 二、董事会会议审议情况 董事会就以下议案进行了审议，经书面和通讯方式表决，通过决 议如下： 具 体 内 容 详 见 公 司 同 日 披 露 于 巨 潮 资 讯 网 （http://www.cninfo.com.cn）的公司《2025年半年度报告》及其摘要。 表决结果：11票同意，0票反对，0票弃权。 该议案已经公司第十一届董事 ...